950160 — Kolon TissueGene Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapMomentum Trap

Annual cashflow statement for Kolon TissueGene, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-42.3	-35.4	-41.4	-8.62	-13.2
Depreciation
Amortisation
Non-Cash Items	4.47	0.244	0.65	-3.45	-2.13
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-0.93	1.47	4.42	-9.94	-4.22
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-37.6	-32.3	-35	-20.7	-18.5
Capital Expenditures	-2.03	-0.712	-5.36	-18.8	-35.4
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	65.7	16.6	34.6	-12.2	13.1
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	63.7	15.9	29.2	-31	-22.2
Financing Cash Flow Items	—	—	—	23.7	—
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-5.07	-5.83	21.5	51.8	29.2
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	21.1	-22.3	15.7	0.056	-11.5